keyword
MENU ▼
Read by QxMD icon Read
search

GNRH Agonist

keyword
https://www.readbyqxmd.com/read/28513550/hcg-triggering-in-art-an-evolutionary-concept
#1
REVIEW
Anat Hershko Klement, Adrian Shulman
Human chorionic gonadotropin (hCG) is no longer a single, omnipotent ovulation triggering option. Gonadotropin releasing hormone (GnRH) agonist, initially presented as a substitute for hCG, has led to a new era of administering GnRH agonist followed by hCG triggering. According to this new concept, GnRH agonist enables successful ovum maturation, while hCG supports the luteal phase and pregnancy until placental shift.
May 17, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28508683/effectiveness-of-mild-ovarian-stimulation-versus-gnrh-agonist-protocol-in-women-undergoing-assisted-reproductive-technology-a-meta-analysis
#2
Yuan Fan, Xiaowei Zhang, Zhidong Hao, Huanfei Ding, Quanyu Chen, Li Tian
OBJECTIVE: our meta-analysis was conducted to evaluate the effectiveness of the mild ovulation induction protocol using CC/gonadotropin/GnRH antagonist compared to the conventional GnRH agonist protocol in women undergoing ART. METHOD: Six electronic databases were searched from their date of establishment until August 2016. Outcomes in our analysis were calculated in terms of relative risk (RR) and weighted mean differences (WMD) and standard mean differences (SMD) with 95% confidence intervals (CI) using random effect models or fixed effect models...
May 16, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28506467/apoptosis-of-bovine-granulosa-cells-intracellular-pathways-and-differentiation
#3
M C Carou, P R Cruzans, A Maruri, M G Farina, C D Fiorito, G Olea, D M Lombardo
Follicular atresia in granulosa and theca cells occurs by apoptosis through weak hormonal stimulation. We have previously proposed an in vitro model to study this process by inducing apoptosis in BGC-1, a bovine granulosa cell line, and in primary cultures from ovaries with or without corpus luteum (CPGB+ and CPGB-, respectively), with different doses of gonadotropin releasing hormone (GnRH) analogs (leuprolide acetate (LA) as agonist and antide as antagonist). BGC-1 represent immature granulosa cells, whereas CPGB represent different degrees of luteinization...
May 12, 2017: Acta Histochemica
https://www.readbyqxmd.com/read/28502234/a-gonadotropin-releasing-hormone-agonist-for-the-prevention-of-docetaxel-induced-gonadal-damage
#4
Ilhae Park, Sanghoon Lee, Ki-Jin Ryu, Kyung-Jin Min, Jin Hwa Hong, Jae Yun Song, Jae Kwan Lee, Nak Woo Lee
This study aimed to evaluate the protective effect of a gonadotropin-releasing hormone (GnRH) agonist against docetaxel-induced gonadotoxicity in a mouse model. Forty mice (female B6, 6-8 weeks old, weighing 16-18 g) were divided randomly into four groups. Groups 1 and 2 were treated with a single intraperitoneal dose of 0.1 mL normal saline; Groups 3 and 4 received 30 mg/kg docetaxel. Groups 2 and 4 were pre-treated with a subcutaneous injection of 0.3 mg leuprolide acetate, 2 weeks before the administration of docetaxel...
May 14, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28501366/reproductive-outcomes-after-a-single-dose-of-gonadotropin-releasing-hormone-agonist-compared-with-human-chorionic-gonadotropin-for-the-induction-of-final-oocyte-maturation-in-hyper-responder-women-aged-35-40%C3%A2-years
#5
Samer Tannus, Rola Turki, Yoni Cohen, Weon-Young Son, Tal Shavit, Michael Haim Dahan
OBJECTIVE: To investigate the reproductive outcomes after the use of GnRH agonist (GnRHa) compared with hCG for the induction of final oocyte maturation in GnRH antagonist cycles performed in hyper-responder women aged 35-40 years. DESIGN: Retrospective study. SETTING: Academic fertility center. PATIENT(S): Two hundred seventy-two hyper-responder women aged 35-40 years who underwent controlled ovarian stimulation under GnRH antagonist suppression were included...
May 10, 2017: Fertility and Sterility
https://www.readbyqxmd.com/read/28480768/degarelix-versus-luteinizing-hormone-releasing-hormone-agonists-for-the-treatment-of-prostate-cancer
#6
Timothy N Clinton, Solomon L Woldu, Ganesh V Raj
Androgen deprivation therapy (ADT) is the mainstay for advanced, hormone-sensitive prostate cancer, and options include surgical castration, luteinizing hormone-releasing hormone (LHRH) agonist, and more recently, gonadotropin releasing hormone (GnRH) antagonist therapy. Our understanding of the mechanisms and adverse effects of ADT has increased substantially, including the class-specific adverse effects of ADT. Areas Covered: This review will summarize the pharmacodynamic and pharmacokinetic properties of the GnRH antagonist degarelix and its role in the management of advanced prostate cancer, the clinical evidence supporting its regulatory approval, as well as potential benefits and disadvantages over traditional LHRH agonist therapy...
May 8, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28475285/involvement-of-neurone-glia-neurone-neurone-communications-via-gap-junctions-in-synchronised-activity-of-kndy-neurones
#7
K Ikegami, S Minabe, N Ieda, T Goto, A Sugimoto, S Nakamura, N Inoue, S Oishi, A D Maturana, M Sanbo, M Hirabayashi, K-I Maeda, H Tsukamura, Y Uenoyama
Pulsatile secretion of the gonadotropin-releasing hormone (GnRH)/luteinizing hormone is indispensable for puberty onset and reproductive activities at adulthood in mammalian species. A cohort of neurones expressing three neuropeptides, kisspeptin, encoded by Kiss1 gene, neurokinin B (NKB) and dynorphin A, localised in the hypothalamic arcuate nucleus (ARC), so-called KNDy neurones, are a putative intrinsic source of the GnRH pulse generator. Synchronous activity among KNDy neurones is thought to be required for pulsatile GnRH secretion...
May 5, 2017: Journal of Neuroendocrinology
https://www.readbyqxmd.com/read/28472240/gnrh-agonist-for-protection-against-ovarian-toxicity-during-chemotherapy-for-early-breast-cancer-the-anglo-celtic-group-option-trial
#8
Rcf Leonard, Dja Adamson, G Bertelli, J Mansi, A Yellowlees, J Dunlop, G A Thomas, R E Coleman, R A Anderson
Background: HASH(0x43756f8) Patients and Methods: HASH(0x437e2b0) Results: HASH(0x3917ee0) Conclusion: HASH(0x437d818) Trial registration: EudraCT 2004-000133-11.
May 2, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28467768/gnrh-agonist-triggering-of-ovulation-replacing-hcg-a-30-year-old-revolution-in-ivf-practice-led-by-rambam-health-care-campus
#9
REVIEW
Shahar Kol, Ofer Fainaru
Final oocyte maturation is a crucial step in in vitro fertilization, traditionally achieved with a single bolus of human chorionic gonadotropin (hCG) given 36 hours before oocyte retrieval. This bolus exposes the patient to the risks of ovarian hyperstimulation syndrome (OHSS), particularly in the face of ovarian hyper-response to gonadotropins. Although multiple measures were developed to prevent OHSS, gonadotropin-releasing hormone (GnRH) agonist triggering is now globally recognized as the best approach to achieve this goal...
April 28, 2017: Rambam Maimonides Medical Journal
https://www.readbyqxmd.com/read/28467398/pathophysiology-and-management-of-urinary-tract-endometriosis
#10
REVIEW
Camran Nezhat, Rebecca Falik, Sara McKinney, Louise P King
Endometriosis predominantly affects the pelvic reproductive organs but can also affect the urinary tract. A number of theories for the pathogenesis of endometriosis have been suggested, but the exact mechanisms remain elusive. Endometriotic lesions can be found on both the ureter and bladder, and the optimal therapeutic approach depends on the extent, depth, and location of these lesions. Medical approaches, including hormonal therapies such as GnRH agonists and oral contraceptives, tend to be a temporary measure, but can be useful in a preoperative setting or if the patient is unsuitable for surgery, and are also useful as a postoperative treatment...
May 3, 2017: Nature Reviews. Urology
https://www.readbyqxmd.com/read/28466954/-downregulation-of-lh-in-the-bitch-after-application-of-the-gnrh-agonist-buserelin-as-a-slow-release-implant
#11
Andrea Piepenbrink, Klaus Failing, Anja Riesenbeck, Peter Schmid, Bernd Hoffmann
OBJECTIVES: Demonstration of downregulation of luteinizing hormone (LH) using the gonadotropin-releasing hormone (GnRH)-agonist buserelin as the active ingredient in the form of a slow-release implant. MATERIAL AND METHODS: To eliminate any negative feedback mechanisms of endogenous sex steroids, nine bitches were ovariohysterectomized prior to treatment. The applied drug was the slow-release implant Profact Depot(®) with the active ingredient buserelin; dosages were 3...
May 3, 2017: Tierärztliche Praxis. Ausgabe K, Kleintiere/Heimtiere
https://www.readbyqxmd.com/read/28462402/letrozole-gnrh-antagonist-stimulation-protocol-in-poor-ovarian-responders-undergoing-intracytoplasmic-sperm-injection-cycles-an-rct
#12
Mahbod Ebrahimi, Firouzeh Akbari-Asbagh, Mojgan Ghalandar-Attar
BACKGROUND: Gonadotropin-releasing hormone (GnRH) antagonist protocol has been proposed as a potentially proper option for the patients with limited ovarian reserve. Nevertheless, there is no significant difference in terms of clinical pregnancy between the GnRH antagonist and agonist cycles. The use of aromatase inhibitors such as letrozole was suggested by some studies. OBJECTIVE: The object of this study was to evaluate the efficacy of letrozole co-treatment with GnRH-antagonist protocol in ovarian stimulation of poor responder patients undergoing intracytoplasmic sperm injection...
February 2017: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://www.readbyqxmd.com/read/28462399/can-letrozole-plus-hmg-protocol-improve-pregnancy-outcomes-in-frozen-thawed-embryo-transfer-an-rct
#13
Ashraf Aleyasin, Marzieh Aghahosseini, Leili Safdarian, Maryam Noorzadeh, Parvin Fallahi, Zahra Rezaeian, Sedighe Hoseinimosa
BACKGROUND: There are different methods in endometrial preparation for frozen-thawed embryo transfer (FET). OBJECTIVE: The purpose of this study was to compare the live birth rate in the artificial FET protocol (estradiol/ progesterone with GnRH-agonist) with stimulated cycle FET protocol (letrozole plus HMG). MATERIALS AND METHODS: This randomized clinical trial included 100 women (18-42 years) randomly assigned to two groups based on Bernoulli distribution...
February 2017: International Journal of Reproductive Biomedicine (Yazd, Iran)
https://www.readbyqxmd.com/read/28459828/individual-luteolysis-pattern-after-gnrh-agonist-trigger-for-final-oocyte-maturation
#14
Barbara Lawrenz, Nicolas Garrido, Suzan Samir, Francisco Ruiz, Laura Melado, Human M Fatemi
Final oocyte maturation using GnRH-agonist trigger in a GnRH-antagonist protocol is increasingly common, as ovarian hyperstimulation syndrome is almost completely avoided. However, this approach might lead to reduced pregnancy rates due to severe luteolysis. This proof of concept study evaluated the extend of luteolysis by measuring progesterone levels 48 hours after oocyte retrieval in 51 patients, who received GnRH-agonist trigger for final oocyte maturation in a GnRH-antagonist protocol due to the risk of ovarian hyperstimulation syndrome...
2017: PloS One
https://www.readbyqxmd.com/read/28459598/practices-and-attitudes-regarding-women-undergoing-fertility-preservation-a-survey-of-the-national-physicians-cooperative
#15
Pietro Bortoletto, Rafael Confino, Brigid M Smith, Teresa K Woodruff, Mary Ellen Pavone
PURPOSE: To describe physician attitudes and variations in oncofertility treatment strategies. METHODS: An exploratory online survey administered between December 1, 2014 and January 27, 2015 to 185 members of the National Physicians Cooperative (NPC). RESULTS: Twenty-eight percent (52 of 185) of NPC members responded to the online survey. Fifty percent of respondents were obstetrician-gynecologists working largely in academic medical centers...
May 1, 2017: Journal of Adolescent and Young Adult Oncology
https://www.readbyqxmd.com/read/28449632/predicting-the-outcome-of-different-protocols-of-in%C3%A2-vitro-fertilization-with-anti-mu%C3%A3-llerian-hormone-levels-in-patients-with-polycystic-ovary-syndrome
#16
Ya Chen, Bilv Ye, Xiaojing Yang, Jiujia Zheng, Jinju Lin, Junzhao Zhao
Objective This study evaluated associations of basal serum and follicular fluid (FF) anti-Muüllerian hormone (AMH) levels with in vitro fertilization (IVF) outcomes in polycystic ovary syndrome (PCOS) patients. Methods This prospective study included 179 consecutive women undergoing IVF, including 59 with PCOS and non-PCOS controls. Thirty PCOS cases had long gona-dotrophin-releasing hormone agonist (GnRH-a) and 29 had antagonist (GnRH-ant) protocols. Controls underwent conventional GnRH-a. Associations of basal serum and FF AMH levels with IVF outcomes were assessed...
January 1, 2017: Journal of International Medical Research
https://www.readbyqxmd.com/read/28447505/does-pituitary-suppression-affect-live-birth-rate-in-women-with-congenital-hypogonadotrophic-hypogonadism-undergoing-intra-cytoplasmic-sperm-injection-a-multicenter-cohort-study
#17
Sezcan Mumusoglu, Baris Ata, Volkan Turan, Berfu Demir, Inci Kahyaoglu, Kiper Aslan, Ayse Seyhan Ata, Bulent Yilmaz, Kayhan Yakin, Berrin Avci, Gurkan Uncu, Gurkan Bozdag
In this retrospective multicenter cohort study, women with congenital hypogonadotrophic hypogonadism (CHH) (n = 57) who underwent intra-cytoplasmic sperm injection in-between 2010-2014 were compared to age-matched controls with tubal factor infertility (n = 114) to assess ovarian stimulation cycle and pregnancy outcomes. Live birth rates (LBRs) per started cycle were 31.6 and 24.6% in CHH and controls groups, respectively (p = 0.36). Comparable success rates were also confirmed with the logistic regression analysis (OR: 1...
April 27, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28444614/combined-gnrh-agonist-and-human-chorionic-gonadotropin-trigger-improves-icsi-cycle-outcomes-in-patients-with-history-of-poor-fertilization
#18
Rony T Elias, Nigel Pereira, Lisa Artusa, Amelia G Kelly, Monica Pasternak, Jovana P Lekovich, Gianpiero D Palermo, Zev Rosenwaks
PURPOSE: The purpose of this study was to investigate the utility of a combined GnRH-agonist (GnRH-a) and human chorionic gonadotropin (hCG) trigger in improving ICSI cycle outcomes in patients with poor fertilization history after standard hCG trigger in prior ICSI cycles. METHODS: Retrospective cohort study. Patients with a fertilization rate of <20% in at least two prior ICSI cycles who subsequently underwent another ICSI cycle with hCG trigger were compared to those who underwent another ICSI cycle with a combined GnRH-a and hCG trigger...
April 13, 2017: Journal of Assisted Reproduction and Genetics
https://www.readbyqxmd.com/read/28444173/tac1-signaling-is-required-for-sexual-maturation-and-responsiveness-of-gnrh-neurons-to-kisspeptin-in-the-male-mouse
#19
Caroline A Maguire, Yong Bhum Song, Min Wu, Silvia León, Rona S Carroll, Meenakshi Alreja, Ursula B Kaiser, Víctor M Navarro
The tachykinins substance P (SP) and neurokinin A (NKA) (Tac1) have emerged as novel regulators of kisspeptin/GnRH release. Recently, we documented that SP modulates reproductive function in the female mouse. Here, we extended this characterization to the male mouse. Tac1-/- male mice showed delayed puberty onset. They also presented significantly decreased expression levels of Pdyn (dynorphin) and Nos1 (nitric oxide synthase) in the mediobasal hypothalamus and elevated Gnrh1 levels. Unexpectedly, the response of Tac1-/- mice to central kisspeptin or senktide (neurokinin B receptor -NK3R- agonist) administration was significantly decreased compared with controls, despite the preserved ability of GnRH neurons to stimulate LH release as demonstrated by central NMDA administration, suggesting a deficit at the GnRH neuron level...
April 21, 2017: Endocrinology
https://www.readbyqxmd.com/read/28443256/change-in-body-mass-index-and-insulin-resistance-after-1-year-treatment-with-gonadotropin-releasing-hormone-agonists-in-girls-with-central-precocious-puberty
#20
Jina Park, Jae Hyun Kim
PURPOSE: Gonadotropin-releasing hormone agonist (GnRHa) is used as a therapeutic agent for central precocious puberty (CPP); however, increased obesity may subsequently occur. This study compared body mass index (BMI) and insulin resistance during the first year of GnRHa treatment for CPP. METHODS: Patient group included 83 girls (aged 7.0-8.9 years) with developed breasts and a peak luteinizing hormone level of ≥5 IU/L after GnRH stimulation. Control group included 48 prepubertal girls...
March 2017: Annals of Pediatric Endocrinology & Metabolism
keyword
keyword
22413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"